Author

H. Pearce

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

J. Zuo· 2 shared P. Moss· 2 shared A. Dowell· 1 shared A. Horsley· 1 shared B. Hallis· 1 shared B. Mahon· 1 shared B. Parker· 1 shared D. Blakeway· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Zuo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma

W. Croft, H. Pearce, S. Margielewska-Davies, L. Lim, S. M. Nicol, F. Zayou, D. Blakeway, F. Marcon, S. Powell-Brett, B. Mahon, R. Merard, J. Zuo, G. Middleton, K. Roberts, R. M. Brown, P. Moss

The paper uses spatial transcriptomics and scRNA-Seq to analyze fibroblast subtypes in pancreatic ductal adenocarcinoma, linking their transcriptomes to clinical outcomes and suggesting therapeutic targets.

bioRxiv · Jan 20, 2023Cancer Biology

Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection

J. Zuo, A. Dowell, H. Pearce, K. Verma, H. Long, J. Begum, F. Aiano, Z. Amin-Chowdhury, B. Hallis, L. Stapley, R. Borrow, E. Linley, S. Ahmad, B. Parker, A. Horsley, , P. Moss

This study shows that SARS-CoV-2-specific T-cell immunity remains robust six months after infection, with response magnitude linked to initial infection severity.

bioRxiv · Nov 1, 2020Immunology